Absci Q4 revenue $0.7M, net loss $29M; pipeline advances and AMD collaboration

Absci Corp

Q4 revenue $0.7M (vs $0.3M YoY); net loss $29.0M vs $23.5M.
Cash & investments $112.4M; sufficient into H1 2027; gross cash burn ~$72M in FY2024.
ABS-101 anti-TL1A to enter Phase 1 in H1 2025; interim data expected H2 2025.
AMD strategic collaboration includes $20M equity investment; AI drug discovery workloads.
Expects to sign one or more drug creation partnerships in 2025, including with Large Pharma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.